A Las Vegas-based cannabinoid company is putting down Ottawa roots in the hope of capitalizing on Canada’s less restrictive cannabis market.
GB Sciences announced Tuesday it is establishing its first non-U.S. footprint, dubbed GBS Global Biopharma, in Ottawa.
A release states that the company’s Canadian entity will research and develop cannabinoid-based medicines with the help of Canada’s legal market, tax credits and favourable exchange rates.
(Sponsored)
Invest with confidence: Hydro Ottawa funds technical studies for business retrofits
For Ottawa businesses, the opportunity to improve building performance has never been greater. Energy retrofits can cut emissions, strengthen operations, extend the life of assets, reduce operating costs, and position
In a tough economy, investing in community is more important than ever
When finances are tight, it might seem counterintuitive to give back, but supporting our most vulnerable neighbours this holiday season can actually help businesses weather their own challenges. At United
Regulatory frameworks north of the border will also foster international collaboration, GB Sciences said. The company’s researchers work with partners in the United States, Spain and Greece on prescription drug programs, cannabinoid delivery technology and nutraceuticals, more commonly known as supplements.
“Canada’s policies will allow GBS Global to bring our next-generation cannabinoid medications to market quickly, safely and legally. Canada’s regulations, in particular, mean treatments can be evaluated and approved in less time than it would take in the U.S.,” said GB Sciences CEO John Poss in a statement.
